Regeneron Pharmaceuticals stock advances 3.02% and outperforms competitors

8 articles · Updated · MarketWatch · Apr 30

The shares closed at $707.06 on Thursday, snapping a four-day losing streak as the S&P 500 rose 1.02% and the Dow gained 1.62%.
Regeneron beat peers including Amgen, up 2.43%, Moderna, up 0.48%, and Gilead Sciences, up 1.55% during the broader market rally.
Trading volume reached 1.1 million shares, above the 50-day average of 658,571, while the stock remained 13.89% below its 52-week high of $821.11.

With Regeneron's stock still nearly 14% below its peak despite strong results, what risks or headwinds could investors be overlooking?

Could the new government pricing deal and R&D commitments signal a lasting shift in how breakthrough drugs are funded and distributed in the U.S.?

How might Regeneron's landmark gene therapy approval and free rollout reshape patient access and the broader pharmaceutical pricing landscape?